| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/26/2000 | CN1261279A Pharmaceutical compositions containing eletriptan hemisulphate and caffeine |
| 07/26/2000 | CN1261277A Novel substituted imidazole compounds |
| 07/26/2000 | CN1261274A Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them. |
| 07/26/2000 | CN1054856C New 19-nor steroids having phenoxyalkylsulphonemide or phenoxyalkylsulphonylurea chain in position llbeta, preparation process and intermediates, use as medicaments and pharmaceutical |
| 07/26/2000 | CN1054768C Traditional Chinese pharmacist-prepared medicine for hypertension and preparation method |
| 07/25/2000 | US6093838 Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 07/25/2000 | US6093822 5-arylindole derivatives |
| 07/25/2000 | US6093812 Process for the stereospecific synthesis of azetidinones |
| 07/25/2000 | US6093743 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 07/25/2000 | US6093729 Substituted bicyclic heteroaroylguanidines, a process for their preparation, their use as a medicament or a diagnostic agent, and a medicament containing them |
| 07/25/2000 | US6093727 A selective agonists for human alpha 2 receptors for treating disorders as hypertension, pain, glaucoma, alcohol and drug withdrawal, ischemia, rheumatoid arthritis, migraine, cognitive deficiency, spasticity, diarrhea, nasal congestion |
| 07/25/2000 | US6093720 An antioxidant, antiischemic as well as antiamnesic effects for inhibiting lipid peroxidation, treating various degenerative neurological diseases alzheimer's disease |
| 07/25/2000 | US6093718 An oxido-squalene cyclase inhibitor, anticholesterol agent for inhibiting cholesterol biosynthesis and lowering cholesterol levels in blood plasma; treating hypercholesterolemia and atherosclerosis |
| 07/25/2000 | US6093717 Imidazopyridine thrombin inhibitors |
| 07/25/2000 | US6093713 A tyrosine kinase inhibitor for enhancing the function of a cholinergic neuron |
| 07/25/2000 | US6093710 Benzothiophene derivatives, their preparation and use as urokinase inhibitors |
| 07/25/2000 | US6093561 Human lysophospholipase |
| 07/25/2000 | US6093532 Method for storing a biological organ transplant graft using a benzisoselen-azoline or -azine compound |
| 07/25/2000 | CA2205285C Benzoic acid derivative and pharmaceutical composition |
| 07/25/2000 | CA2167688C Methods and compositions for inhibiting uridine secretion |
| 07/20/2000 | WO2000042216A2 Genetic predisposition to abnormal calcification conditions |
| 07/20/2000 | WO2000042211A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith |
| 07/20/2000 | WO2000042179A2 Complex-forming proteins |
| 07/20/2000 | WO2000042173A1 Catalytic molecules |
| 07/20/2000 | WO2000042071A2 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | WO2000042070A1 Mammalian alpha-helical protein - 12 |
| 07/20/2000 | WO2000042066A1 Method of purifying whey of lactic acid fermentation by electrodialysis |
| 07/20/2000 | WO2000042042A2 High affinity inhibitors for target validation and uses thereof |
| 07/20/2000 | WO2000042040A1 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 07/20/2000 | WO2000042038A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | WO2000042037A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | WO2000042036A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | WO2000042035A1 4-(heterocyclylsulfonamido) -5-methoxy-6- (2-methoxyphenoxy) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists |
| 07/20/2000 | WO2000042031A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 07/20/2000 | WO2000042030A1 Hypolipidemic and antioxidant morpholine derivatives |
| 07/20/2000 | WO2000042029A1 1-heterocycle substituted diarylamines |
| 07/20/2000 | WO2000042027A1 Novel polyhydroxypyrazine derivatives, preparation and pharmaceutical compositions containing same |
| 07/20/2000 | WO2000042024A1 Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt |
| 07/20/2000 | WO2000042023A1 Substituted imidazoles, their preparation and use |
| 07/20/2000 | WO2000042022A1 Benzoheterocycles and their use as mek inhibitors |
| 07/20/2000 | WO2000042020A1 Phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | WO2000042018A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | WO2000042013A1 Cinnamamide derivatives and drug compositions containing the same |
| 07/20/2000 | WO2000042004A1 Benzenic sulphonamide derivatives and their uses |
| 07/20/2000 | WO2000042003A1 Benzenesulfonamide derivatives and their use as mek inhibitors |
| 07/20/2000 | WO2000042002A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 07/20/2000 | WO2000041994A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/20/2000 | WO2000041727A1 Transcutaneous photodynamic treatment of targeted cells |
| 07/20/2000 | WO2000041726A2 Noninvasive vascular therapy |
| 07/20/2000 | WO2000041712A1 Inhibiting development of microvessels within vascular walls |
| 07/20/2000 | WO2000041699A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones |
| 07/20/2000 | WO2000041697A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia |
| 07/20/2000 | WO2000041696A1 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 07/20/2000 | WO2000041695A1 Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia |
| 07/20/2000 | WO2000041687A2 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 07/20/2000 | WO2000041677A1 Granules for oral administration, process for producing the same, and tablets produced from the granules |
| 07/20/2000 | WO2000041669A2 Benzimidazole vascular damaging agents |
| 07/20/2000 | WO2000041566A1 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/20/2000 | WO2000041545A2 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | WO2000041531A2 Serine protease inhibitors |
| 07/20/2000 | WO2000041505A2 Anthranilic acid derivatives |
| 07/20/2000 | WO2000041481A2 Medicament forms having controlled release and containing active substances which easily dissolve in water |
| 07/20/2000 | WO2000041472A2 Binding partners for 5-ht5-receptors for the treatment of migraine |
| 07/20/2000 | WO2000041469A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS |
| 07/20/2000 | WO2000024885A3 p53 MORPHOLINO-BASED ANTISENSE |
| 07/20/2000 | WO2000021521A3 Sertraline oral concentrate |
| 07/20/2000 | WO2000020572A3 Tissue binding peptides, identification, production and utilization thereof |
| 07/20/2000 | WO2000017358A3 Human chaperone proteins |
| 07/20/2000 | WO2000015783A3 ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO β1-ADRENOCEPTOR-SPECIFIC mRNA AND METHODS OF USE |
| 07/20/2000 | WO2000002902A9 Novel inhibitors of angiogenesis and tumor growth |
| 07/20/2000 | WO2000001687A9 Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 07/20/2000 | WO1997025042A8 Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x |
| 07/20/2000 | DE19901040A1 Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe Controlled release dosage forms containing highly water-soluble drugs |
| 07/20/2000 | CA2697598A1 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | CA2370042A1 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | CA2360584A1 Mammalian alpha-helical protein - 12 |
| 07/20/2000 | CA2360387A1 Catalytic molecules |
| 07/20/2000 | CA2360386A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2360356A1 .beta.-phenylalanine derivatives as integrin antagonists |
| 07/20/2000 | CA2359952A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | CA2359942A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | CA2359798A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith |
| 07/20/2000 | CA2359562A1 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 07/20/2000 | CA2359479A1 Novel complex-forming proteins |
| 07/20/2000 | CA2359461A1 Inhibiting development of microvessels within vascular walls |
| 07/20/2000 | CA2359390A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia |
| 07/20/2000 | CA2359381A1 Medicament forms having controlled release and containing active substances which easily dissolve in water |
| 07/20/2000 | CA2359253A1 Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia |
| 07/20/2000 | CA2358638A1 Composition and methods for administration of water-insoluble paclitaxel derivatives |
| 07/20/2000 | CA2356934A1 Serine protease inhibitors |
| 07/20/2000 | CA2356776A1 Transcutaneous photodynamic treatment of targeted cells |
| 07/20/2000 | CA2356532A1 Noninvasive vascular therapy |
| 07/20/2000 | CA2356290A1 Benzenic sulphonamide derivatives and their uses |
| 07/20/2000 | CA2355374A1 1-heterocycle substituted diarylamines |
| 07/20/2000 | CA2352509A1 Cinnamamide derivatives and pharmaceutical compositions containing the same |
| 07/20/2000 | CA2349832A1 Benzenesulfonamide derivatives and their use as mek inhibitors |
| 07/20/2000 | CA2349467A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 07/20/2000 | CA2349180A1 Anthranilic acid derivatives |
| 07/20/2000 | CA2348236A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/20/2000 | CA2296224A1 Use of imidazo(1,5-a)pyrido(3,2-e)pyrazinones |